Prelude Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Prelude Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,973	Closed	-$95.7K	–	1422
2023 Q1	$95.7K	Buy	+10,973	New	+$87.8K	0.01%	955
2019 Q3	–	Sell	-767	Closed	-$5K	–	2159
2019 Q2	$5K	Buy	+767	New	+$8.69K	﹤0.01%	1526
2019 Q1	–	Sell	-905	Closed	-$7K	–	2288
2018 Q4	$7K	Buy	905 +95	+12%	+$904	﹤0.01%	1489
2018 Q3	$9K	Buy	+810	New	+$10.1K	﹤0.01%	1492
2018 Q2	–	Sell	-906	Closed	-$12K	–	2011
2018 Q1	$12K	Buy	906 +416	+85%	+$5.17K	﹤0.01%	1345
2017 Q4	$5K	Sell	490 -6,610	-93%	-$56.5K	﹤0.01%	1269
2017 Q3	$57K	Buy	+7,100	New	+$48K	0.01%	1065

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Prelude Capital Management's CBAY Position: Q2 2023 in Review

Prelude Capital Management sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 10,973 shares — an estimated $95.7K sold.

Prelude Capital Management first reported a position in CBAY in Q3 2017 and held it in 7 quarters. The position peaked at $95.7K in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

Prelude Capital Management reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
Prelude Capital Management sold 10,973 Cymabay Therapeutics shares in Q2 2023, an estimated $95.7K.
Prelude Capital Management first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 7 quarters.
Prelude Capital Management's Cymabay Therapeutics position peaked at $95.7K in Q1 2023.
151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.